截至本公告日期，H股全流通及转换并上市的实施计划详情尚未最终落实。本公司将在适当时候根据内 幕消息条文及╱或上市规则的要求，就H股全流通及转换并上市的进展作出进一步公告。 友芝友生物-B(02496)发布公告，本公司近期已就H股全流通向中国证监会提交备案(中国证监会备案)。 本公司已向中国证监会提交备案申请，拟将合共6801.03万股本公司内资股及非上市外资股转换为H股并 于联交所上市(转换并上市)。董事会欣然宣布，本公司接获日期为2026年1月13日有关转换并上市的备 案通知。根据备案通知，有关转换并上市的中国证监会备案已告完成，倘本公司拟于备案通知发出日期 起12个月内未完成转换并上市，拟继续推进的，则需向中国证监会提交更新后的备案。 ...

汇通达网络(09878)公布，就拟实施H股全流通，公司已收到香港联交所于2026年1月21日授出的就 349,749,813股H股上市的批准。公司将完成就转换H股的相关转换及交易程序。此举有助于H股流通性 与市场影响力，为后续重新纳入港股通创造了积极条件。 ...

Core Viewpoint - The company, HuTongDa Network (9878.HK), has received a filing notice from the China Securities Regulatory Commission regarding the full circulation of H-shares, which will significantly increase its market capitalization in Hong Kong stocks [1] Group 1: H-share Conversion - HuTongDa has completed the filing for the conversion of over 349 million domestic shares into H-shares, which will raise the circulation ratio of H-shares from 32% to 94% [1] - This conversion is expected to significantly enhance the liquidity of HuTongDa's shares in the Hong Kong market and may meet the inclusion criteria for the Hong Kong Stock Connect program [1] Group 2: Strategic Initiatives - Since 2025, the company has been deepening its "smart supply chain" and "AI+SaaS" strategic layout, entering new models and sectors such as fast-moving consumer goods and community hard discount retail [1] - Market expectations suggest that the ongoing strategic upgrades and the implementation of innovative scenarios will lead to sustained and stable growth for the company [1]

Core Viewpoint - The company has received a filing notice from the China Securities Regulatory Commission regarding the full circulation of H-shares, effective from January 15, 2026 [1] Group 1 - The company has completed the filing for the conversion of a total of 349,749,813 domestic shares into H-shares [1] - The filing notice is valid for 12 months starting from January 15, 2026 [1]

Core Viewpoint - The company, 毛戈平 (01318), has received a notice from the China Securities Regulatory Commission regarding the implementation of full circulation of H-shares, allowing for the conversion of 228 million unlisted shares into H-shares, effective from January 13, 2026, for a period of 12 months [1]. Group 1 - The company will implement full circulation of a total of 228,344,600 unlisted shares, which currently represent 46.58% of the total issued shares [1]. - After the conversion and listing, the total number of H-shares will increase to 490,186,900, representing 100% of the total issued shares [1]. - The company plans to apply for approval from the Hong Kong Stock Exchange for the listing and trading of the relevant H-shares [1]. Group 2 - As of the announcement date, the implementation plan for the full circulation and conversion of H-shares has not been finalized, and the company will provide further updates in accordance with relevant regulations [1].

Core Viewpoint - The public float of the company is approximately 22.58%, which is below the minimum requirement of 25% set by the Hong Kong Stock Exchange [1] Group 1: Public Float and Compliance - The public float is below the minimum percentage due to 3,226,200 shares (approximately 2.42% of the total issued shares) held by Bank of China International Trust (Hong Kong) Limited for non-core connected persons [1] - These shares have not yet been granted to participants, thus they are not considered part of the public float [1] Group 2: H-share Full Circulation Plan - The company plans to implement an H-share full circulation plan [1] - Upon obtaining all necessary approvals and complying with applicable laws and regulations, 65,081,360 shares of domestic unlisted shares (approximately 48.81% of the total issued share capital) held by participating shareholders will be converted into H-shares [1] - This conversion aims to restore the public float to the minimum percentage required by the listing rules [1]

Core Viewpoint - The company, Mengjinyuan (02585), has announced plans to implement full circulation for 40 million unlisted shares held by a shareholder, representing approximately 14.65% of the company's total issued share capital as of the announcement date [1] Group 1 - The company has received a filing notice from the China Securities Regulatory Commission (CSRC) regarding the implementation of full circulation for its H-shares [1] - The company has completed the filing with the CSRC to convert the 40 million unlisted shares into H-shares [1] - The validity period of the filing notice is 12 months from the date of issuance [1] Group 2 - The company will apply to the Stock Exchange for approval of the listing and trading of the relevant H-shares [1] - As of the announcement date, the details of the full circulation and the conversion and listing of related shares have not been finalized [1] - The company anticipates that upon completion of the conversion and listing, all issued shares will be H-shares [1]

Core Viewpoint - The recent transfer of shares by Shanxi Installation indicates a strategic move towards enhancing liquidity and market presence through the conversion of domestic shares to H-shares, which could potentially attract more investors [2] Group 1: Share Transfer Details - On January 12, Shanxi Installation's shareholders transferred shares from GF Securities Hong Kong to Shanxi International Securities, with a total market value of HKD 123 million, accounting for 14.50% of the shares [2] Group 2: H-share Conversion - Shanxi Installation's board approved a proposal to convert 1 billion domestic shares into H-shares, which represents approximately 72.81% of the company's total issued share capital as of the announcement date [2] - The proposed conversion of domestic shares into H-shares is subject to approval from the China Securities Regulatory Commission and the Hong Kong Stock Exchange [2]

Group 1 - The core viewpoint of the article highlights the transfer of shares of Shanxi Installation (02520) from GF Securities Hong Kong to Shanxi International Securities, with a market value of HKD 123 million, representing 14.50% of the total shares [1] - Shanxi Installation announced that on November 21, 2025, its board approved a proposal to convert 1 billion domestic shares into H-shares, which will account for approximately 72.81% of the company's total issued share capital as of the announcement date [1] - The conversion of domestic shares to H-shares is subject to approval from the China Securities Regulatory Commission and the Hong Kong Stock Exchange [1]

Core Viewpoint - Changfeng Pharmaceutical (02652) has submitted a filing application to the China Securities Regulatory Commission (CSRC) regarding the proposed implementation of full circulation of H-shares, converting approximately 107.4 million unlisted domestic shares into H-shares on a one-to-one basis [1] Group 1 - The company plans to convert approximately 107.4 million unlisted shares into H-shares, which will then be listed and traded on the Hong Kong Stock Exchange [1] - The conversion is contingent upon completing all regulatory requirements, including filing with the CSRC and obtaining necessary approvals from the Hong Kong Stock Exchange [1] - Upon completion, the 107.4 million unlisted shares will be converted into an equal number of H-shares [1]